[177Lu-DOTA0-Tyr3]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney-Reference-Cited by-同舟云学术

[177Lu-DOTA0-Tyr3]-Octreotate Treatment in Patients with Disseminated Gastroenteropancreatic Neuroendocrine Tumors: The Value of Measuring Absorbed Dose to the Kidney

Published:2010-01-12 Issue:6 Volume:34 Page:1368-1372
ISSN:0364-2313
Container-title:World Journal of Surgery
language:en
Short-container-title:World J Surg

Author:

Swärd Christina,Bernhardt Peter,Ahlman Håkan,Wängberg Bo,Forssell-Aronsson Eva,Larsson Maria,Svensson Johanna,Rossi-Norrlund Rauni,Kölby Lars

Publisher

Springer Science and Business Media LLC

Subject

Surgery

Link

http://link.springer.com/content/pdf/10.1007/s00268-009-0387-6.pdf

Reference28 articles.

1. Wängberg B, Westberg G, Tylén U et al (1996) Survival of patients with disseminated midgut carcinoid tumors after aggressive tumor reduction. World J Surg 20:892–899, discussion 899

2. Swärd C, Johanson V, Nieveen van Dijkum E et al (2009) Prolonged survival after hepatic artery embolization in patients with midgut carcinoid syndrome. Br J Surg 96:517–521

3. Öberg K (2000) Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 62(Suppl 1):92–97

4. Kölby L, Persson G, Franzén S et al (2003) Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90:687–693

5. Öberg K (2003) Diagnosis and treatment of carcinoid tumors. Expert Rev Anticancer Ther 3:863–877

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic Antitumor Effects of 177Lu-Octreotide Combined with an ALK Inhibitor in a High-Risk Neuroblastoma Xenograft Model;Therapeutics;2024-08-07

2. Optimization of the number of post-therapeutic planar imaging time points for the most reliable organ and tumour dosimetry in peptide receptor radionuclide therapy;Health and Technology;2024-05-01

3. Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review;Clinical and Translational Imaging;2023-09-20

4. Association between fibrosis markers and kidney function following peptide receptor radionuclide therapy in patients with neuroendocrine tumours;Scandinavian Journal of Clinical and Laboratory Investigation;2022-09-21

5. Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study;Journal of Clinical Medicine;2022-02-10